School of Nursing, University of South China, Hengyang, Hunan, 421001, China.
Guangxi Key Laboratory of Diabetic Systems Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin Medical University, Guilin, 541100, China.
J Cardiovasc Transl Res. 2021 Oct;14(5):857-872. doi: 10.1007/s12265-021-10108-w. Epub 2021 Feb 25.
N6-methyladenosine (mA) is the most abundant and prevalent epigenetic modification of mRNA in mammals. This dynamic modification is regulated by mA methyltransferases and demethylases, which control the fate of target mRNAs through influencing splicing, translation and decay. Recent studies suggest that mA modification plays an important role in the progress of cardiac remodeling and cardiomyocyte contractile function. However, the exact roles of mA in cardiovascular diseases (CVDs) have not been fully explained. In this review, we summarize the current roles of the mA methylation in the progress of CVDs, such as cardiac remodeling, heart failure, atherosclerosis (AS), and congenital heart disease. Furthermore, we seek to explore the potential risk mechanisms of mA in CVDs, including obesity, inflammation, adipogenesis, insulin resistance (IR), hypertension, and type 2 diabetes mellitus (T2DM), which may provide novel therapeutic targets for the treatment of CVDs.
N6-甲基腺苷（mA）是哺乳动物 mRNA 中最丰富和普遍的表观遗传修饰。这种动态修饰受 mA 甲基转移酶和去甲基酶调控，通过影响剪接、翻译和降解来控制靶 mRNA 的命运。最近的研究表明，mA 修饰在心脏重构和心肌收缩功能的进展中起着重要作用。然而，mA 在心血管疾病（CVDs）中的确切作用尚未得到充分解释。在这篇综述中，我们总结了 mA 甲基化在 CVDs 进展中的作用，如心脏重构、心力衰竭、动脉粥样硬化（AS）和先天性心脏病。此外，我们试图探讨 mA 在 CVDs 中的潜在风险机制，包括肥胖、炎症、脂肪生成、胰岛素抵抗（IR）、高血压和 2 型糖尿病（T2DM），这可能为 CVDs 的治疗提供新的治疗靶点。
